Výsledky vyhledávání - Xu, Xu Steven
- Zobrazuji výsledky 1 - 13 z 13
-
1
-
2
-
3
-
4
-
5
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes Autor Xu, Xu Steven, Moore, Kenneth, Burton, Paul, Stuyckens, Kim, Mueck, Wolfgang, Rossenu, Stefaan, Plotnikov, Alexei, Gibson, Michael, Vermeulen, An
Vydáno 2012Text -
6
Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity Autor Xu, Xu Steven, Yuan, Min, Zhu, Hao, Yang, Yaning, Wang, Hui, Zhou, Honghui, Xu, Jinfeng, Zhang, Liping, Pinheiro, Jose
Vydáno 2018Text -
7
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment Autor Clemens, Pamela L., Yan, Xiaoyu, Lokhorst, Henk M., Lonial, Sagar, Losic, Nedjad, Khan, Imran, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Zhou, Honghui, Puchalski, Thomas, Xu, Xu Steven
Vydáno 2016Text -
8
Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency Autor Auchus, Richard J., Buschur, Elizabeth O., Chang, Alice Y., Hammer, Gary D., Ramm, Carole, Madrigal, David, Wang, George, Gonzalez, Martha, Xu, Xu Steven, Smit, Johan W., Jiao, James, Yu, Margaret K.
Vydáno 2014Text -
9
Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma Autor Yan, Xiaoyu, Xu, Xu Steven, Weisel, Katja C., Mateos, Maria‐Victoria, Sonneveld, Pieter, Dimopoulos, Meletios A., Usmani, Saad Zafar, Bahlis, Nizar J., Puchalski, Thomas, Ukropec, Jon, Bellew, Kevin, Ming, Qi, Sun, Steven, Zhou, Honghui
Vydáno 2020Text -
10
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses Autor Xu, Xu Steven, Moreau, Philippe, Usmani, Saad Z., Lonial, Sagar, Jakubowiak, Andrzej, Oriol, Albert, Krishnan, Amrita, Bladé, Joan, Luo, Man, Sun, Yu-Nien, Zhou, Honghui, Nnane, Ivo, Deraedt, William, Qi, Ming, Ukropec, Jon, Clemens, Pamela L.
Vydáno 2020Text -
11
Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma Autor Xu, Xu Steven, Dimopoulos, Meletios A., Sonneveld, Pieter, Ho, P. Joy, Belch, Andrew, Leiba, Merav, Capra, Marcelo, Gomez, David, Medvedova, Eva, Iida, Shinsuke, Min, Chang-Ki, Schecter, Jordan, Jansson, Richard, Zhang, Liping, Sun, Yu-Nien, Clemens, Pamela L.
Vydáno 2018Text -
12
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma Autor Casneuf, Tineke, Xu, Xu Steven, Adams, Homer C., Axel, Amy E., Chiu, Christopher, Khan, Imran, Ahmadi, Tahamtan, Yan, Xiaoyu, Lonial, Sagar, Plesner, Torben, Lokhorst, Henk M., van de Donk, Niels W. C. J., Clemens, Pamela L., Sasser, A. Kate
Vydáno 2017Text -
13
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma Autor Yan, Xiaoyu, Clemens, Pamela L., Puchalski, Thomas, Lonial, Sagar, Lokhorst, Henk, Voorhees, Peter M., Usmani, Saad, Richardson, Paul G., Plesner, Torben, Liu, Kevin, Orlowski, Robert Z., Losic, Nedjad, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Ruixo, Juan Jose Perez, Zhou, Honghui, Xu, Xu Steven
Vydáno 2017Text